Cargando…

Metabolic dysfunction–associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study

BACKGROUND AND AIMS: Recently metabolic dysfunction–associated fatty liver disease (MAFLD) has been introduced and was defined as hepatic steatosis with either overweight, diabetes, and/or a combination of other metabolic risk factors. We investigated the application of the MAFLD criteria as compare...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Kleef, Laurens A., Ayada, Ibrahim, Alferink, Louise J.M., Pan, Qiuwei, de Knegt, Robert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299928/ https://www.ncbi.nlm.nih.gov/pubmed/34453359 http://dx.doi.org/10.1002/hep.32131

Ejemplares similares

Objectively Measured Physical Activity Is Inversely Associated With Nonalcoholic Fatty Liver Disease: The Rotterdam Study
por: van Kleef, Laurens A., et al.
Publicado: (2022)

Association of Nonalcoholic Fatty Liver Disease and Fibrosis With Incident Dementia and Cognition: The Rotterdam Study
por: Xiao, Tian, et al.
Publicado: (2022)

Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study
por: Zhang, Xiaofang, et al.
Publicado: (2020)

Metabolic dysfunction‐associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality
por: van Kleef, Laurens A., et al.
Publicado: (2023)

The Steatosis-associated fibrosis estimator (SAFE) score: validation in the general US population
por: van Kleef, Laurens A., et al.
Publicado: (2023)

Dissecting the multifaceted impact of statin use on fatty liver disease: A multidimensional study
por: Ayada, Ibrahim, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution
por: Alferink, Louise Johanna Maria, et al.
Publicado: (2019)

Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B
por: van Kleef, Laurens A., et al.
Publicado: (2021)

Fatty Liver Index and mortality after myocardial infarction: A prospective analysis in the Alpha Omega Cohort
por: Heerkens, Luc, et al.
Publicado: (2023)

Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study
por: van Kleef, Laurens A., et al.
Publicado: (2023)

Association of Metabolic Dysfunction-Associated Fatty Liver Disease and Liver Stiffness With Bone Mineral Density in American Adults
por: Li, Hejun, et al.
Publicado: (2022)

Adherence to a plant-based, high-fibre dietary pattern is related to regression of non-alcoholic fatty liver disease in an elderly population
por: Alferink, Louise J. M., et al.
Publicado: (2020)

The Association Between Cholecystectomy, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease: A Population-Based Study
por: Latenstein, Carmen S. S., et al.
Publicado: (2020)

Reply to: “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
por: van Kleef, Laurens A., et al.
Publicado: (2022)

Significant Association between Subclinical Left Cardiac Dysfunction and Liver Stiffness in Metabolic Syndrome Patients with Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease
por: Apostu, Alexandru, et al.
Publicado: (2023)

Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
por: Han, A Lum
Publicado: (2022)

The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease
por: Martín-Mateos, Rosa, et al.
Publicado: (2021)

Significant Association Between Left Ventricular Diastolic Dysfunction, Left Atrial Performance and Liver Stiffness in Patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease
por: Parvanescu, Tudor, et al.
Publicado: (2021)

Plasma MicroRNA Signature of Alcohol Consumption: The Rotterdam Study
por: Karabegović, Irma, et al.
Publicado: (2022)

Cardiometabolic characterization in metabolic dysfunction–associated fatty liver disease
por: Perdomo, Carolina M., et al.
Publicado: (2022)

Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
por: Alam, Shahinul, et al.
Publicado: (2021)

Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation
por: Han, Ma Ai Thanda, et al.
Publicado: (2021)

Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease
por: Kawamura, Nobuyoshi, et al.
Publicado: (2022)

Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease
por: Yang, Xinyu, et al.
Publicado: (2021)

Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents
por: Ciardullo, Stefano, et al.
Publicado: (2022)

Fatty liver with metabolic disorder, such as metabolic dysfunction‐associated fatty liver disease, indicates high risk for developing diabetes mellitus
por: Miyake, Teruki, et al.
Publicado: (2022)

Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B
por: Li, Juan, et al.
Publicado: (2017)

Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update
por: Alharthi, Jawaher, et al.
Publicado: (2022)

Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions
por: Lee, Jung Il
Publicado: (2022)

Therapeutic developments in metabolic dysfunction-associated fatty liver disease
por: Shi, Yiwen, et al.
Publicado: (2022)

Can we predict the future of patients with liver cirrhosis using volumetrics?
por: Lantinga, Marten A., et al.
Publicado: (2022)

The interleukin-6 –174 G/C promoter polymorphism and arterial stiffness; the Rotterdam Study
por: Sie, Mark PS, et al.
Publicado: (2008)

Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease
por: Sharpton, Suzanne R., et al.
Publicado: (2018)

Postprandial dysfunction in fatty liver disease
por: Grandt, Josephine, et al.
Publicado: (2023)

Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
por: Jung, Han Na, et al.
Publicado: (2023)

Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes
por: Lim, Tae Seop, et al.
Publicado: (2023)

Is Fasting Good When One Is at Risk of Liver Cancer?
por: Minciuna, Iulia, et al.
Publicado: (2022)

Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: The Prognostic Role of Liver Stiffness Measurement
por: Cerrito, Lucia, et al.
Publicado: (2023)

Arterial Stiffness, Biomarkers of Liver Fat, and the Development of Metabolic Dysfunction in Metabolically Healthy Population: A Prospective Study
por: Lin, Lin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l3b15f7aaafd4gc0g1i2plpor9